共 215 条
[1]
Burstein HJ(2010)American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer J Clin Oncol 28 3784-3796
[2]
Prestrud AA(2010)The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial Breast Cancer Res Treat 119 145-153
[3]
Seidenfeld J(1995) measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer Clin Cancer Res 1 1511-1515
[4]
Anderson H(2012)Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial J Clin Oncol 30 3967-3975
[5]
Buchholz TA(2011)Effect of obesity on prognosis after early-stage breast cancer J Clin Oncol 29 25-31
[6]
Davidson NE(2012)Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer J Clin Oncol 30 2977-2980
[7]
Gelmon KE(2002)Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study J Clin Oncol 20 751-757
[8]
Giordano SH(2013)The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer—an analysis of the randomized ABCSG 6a trial Br J Cancer 109 589-596
[9]
Hudis CA(2010)Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy Crit Rev Oncol Hematol 73 156-166
[10]
Malin J(2013)Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective datatbase analysis Breast Cancer Res Treat 138 185-191